Taken together, our present findings and those reported previously by others suggest that PGAM5 is a core regulator in metabolic disease and is a promising candidate target for the design of novel cardioprotective drugs against DCM. The gene discussed is PGAM5; the disease is familial dilated cardiomyopathy.